Beech Biotech is unlocking novel biology to create breakthrough treatments for preeclampsia and other complications of pregnancy. Each year, preeclampsia causes the deaths of 70,000 mothers, 500,000 babies worldwide. Beyond that, long-term health consequences affect 300 million surviving mothers and their preterm infants. A key unmet need are medicines that treat only the mother without exposing the fetus to additional risk. We are addressing this need by developing “Mother only” monoclonals, achieved by a patented modification that blocks antibodies from crossing the placenta. Our lead asset, MOm303, binds and eliminates maternal sFlt-1, a known cause of vascular breakdown in preeclampsia, and releases placental growth factor, thus restoring the healthy balance of these factors. This has the potential to prolong pregnancy and reduce the consequences of preterm birth
Company Details
- Employees
- 2
- Founded
- -
- Address
- This Critical Unmet Need By Targeting Key Drivers Of Preeclampsia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.beech-biotech.com
- Keywords
- Houston.
Beech Biotech Sa Questions
Beech Biotech Sa's website is http://www.beech-biotech.com
Beech Biotech Sa's LinkedIn profile is https://www.linkedin.com/company/beech-biotech-sa
Beech Biotech Sa has
2 employees.
View email and phone details for 2
employees at Beech Biotech Sa.
Beech Biotech Sa's industry is
Biotechnology Research
Beech Biotech Sa's top competitors are
Xterna,
June Health,
Gefjon Pharma,
Proxi Biotech,
Incipiam Pharma,
Synuca Therapeutics,
Lilli Health,
Stalicla,
Akasi Pharma,
3sonic.
Beech Biotech Sa's categories are Biotechnology Research
Beech Biotech Sa's founding year is 2022
